Drug Approval | August 19, 2024
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
The inspection was concluded with zero observations
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Revolutionary technology will further boost OneSource’s scientific services offerings
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
Subscribe To Our Newsletter & Stay Updated
